[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]

November 2017 - July 1883

Decade

Year

Issue

June 20, 2017, Vol 317, No. 23, Pages 2347-2460

In This Issue of JAMA

Highlights

Abstract Full Text
free access has audio
JAMA. 2017;317(23):2347-2349. doi:10.1001/jama.2016.13174
Viewpoint

Management of Chronic Pain in the Aftermath of the Opioid Backlash

Abstract Full Text
JAMA. 2017;317(23):2365-2366. doi:10.1001/jama.2017.4884

This Viewpoint argues that abandoning opioids on principal may be premature and could harm patients successfully treating their chronic pain with opioids.

Primary Care of Patients With Chronic Pain

Abstract Full Text
JAMA. 2017;317(23):2367-2368. doi:10.1001/jama.2017.5787

This Viewpoint advocates for reducing opioid misuse among primary care patients with chronic pain through a comprehensive approach emphasizing shared decision making, nonpharmacological treatments, nonopioid therapy, and a focus on functional improvement rather than pain elimination.

Text Messaging and Protected Health InformationWhat Is Permitted?

Abstract Full Text
JAMA. 2017;317(23):2369-2370. doi:10.1001/jama.2017.5646

This Viewpoint discusses the best use of texting clinical information, noting that neither Health Insurance Portability and Accountability Act nor the Health Information Technology for Economic and Clinical Health Act offer specific guidelines.

The Next Generation of Episode-Based Payments

Abstract Full Text
JAMA. 2017;317(23):2371-2372. doi:10.1001/jama.2017.5902

This Viewpoint discusses bundled payment models and suggests ways in which the next generation of episode-based payments can better align with population health.

A Piece of My Mind

Speak Up

Abstract Full Text
JAMA. 2017;317(23):2373-2374. doi:10.1001/jama.2017.2022
Editorial

Losing Weight During the Postpartum Period

Abstract Full Text
JAMA. 2017;317(23):2375-2376. doi:10.1001/jama.2017.7036

Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal CancerNo Difference, but Not the Same

Abstract Full Text
JAMA. 2017;317(23):2376-2378. doi:10.1001/jama.2017.6673

Putting the US Preventive Services Task Force Recommendation for Childhood Obesity Screening in Context

Abstract Full Text
JAMA. 2017;317(23):2378-2380. doi:10.1001/jama.2017.3434
Original Investigation

Effect of an Internet-Based Program on Weight Loss for Low-Income Postpartum WomenA Randomized Clinical Trial

Abstract Full Text
JAMA. 2017;317(23):2381-2391. doi:10.1001/jama.2017.7119

This cluster randomized clinical trial assessed the effects of adding an internet-based weight loss intervention program to the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC program) on weight loss over 12 months among low-income, postpartum women.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal CancerA Randomized Clinical Trial

Abstract Full Text
JAMA. 2017;317(23):2392-2401. doi:10.1001/jama.2017.7105

This randomized clinical trial compares the effect of adding bevacizumab vs cetuximab to standard chemotherapy regimens on overall survival among patients with advanced or metastatic KRAS wild-type colorectal cancer.

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Abstract Full Text
JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112

This cohort study estimates age-specific risks of breast, ovarian, and contralateral breast cancer among carriers of BRCA1 and BRCA2 mutations and evaluates risk modification by family cancer history and location of the mutation within the BRCA gene.

US Preventive Services Task Force

Recommendation Statement

Screening for Obesity in Children and AdolescentsUS Preventive Services Task Force Recommendation Statement

Abstract Full Text
free access has active quiz has audio
JAMA. 2017;317(23):2417-2426. doi:10.1001/jama.2017.6803

This Recommendation Statement from the US Preventive Services Task Force recommends that clinicians screen for obesity in children and adolescents 6 years and older and offer or refer them to comprehensive, intensive behavioral interventions to promote improvements in weight (B recommendation).

Evidence Report

Screening for Obesity and Intervention for Weight Management in Children and AdolescentsEvidence Report and Systematic Review for the US Preventive Services Task Force

Abstract Full Text
free access has active quiz
JAMA. 2017;317(23):2427-2444. doi:10.1001/jama.2017.0332

This Evidence Report and systematic review to support the 2017 US Preventive Services Task Force Recommendation Statement on screening for obesity summarizes current evidence on the benefits and harms of screening and treatment for obesity and overweight in children and adolescents.

JAMA Performance Improvement

Phenytoin Toxicity

Abstract Full Text
has active quiz has audio
JAMA. 2017;317(23):2445-2446. doi:10.1001/jama.2017.6881

This JAMA Performance Improvement article uses the case of a patient with iatrogenic phenytoin toxicity due to an excess prescribed dosage to discuss proper handling and reporting of significant adverse drug events.

Research Letter

Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014

Abstract Full Text
JAMA. 2017;317(23):2448-2450. doi:10.1001/jama.2017.4392

This study uses NHANES data to assess trends in supplemental vitamin D intake of 1000 IU or more and 4000 IU or more daily between 1999 and 2014.

Comment & Response

Changes in Coronary Artery Plaque With Testosterone Therapy

Abstract Full Text
JAMA. 2017;317(23):2450. doi:10.1001/jama.2017.6016

Temporal Changes in Subsequent Malignancies Among Childhood Cancer Survivors

Abstract Full Text
JAMA. 2017;317(23):2451. doi:10.1001/jama.2017.6020

Changes in Coronary Artery Plaque With Testosterone Therapy—Reply

Abstract Full Text
JAMA. 2017;317(23):2451. doi:10.1001/jama.2017.6024

Temporal Changes in Subsequent Malignancies Among Childhood Cancer Survivors—Reply

Abstract Full Text
JAMA. 2017;317(23):2451-2452. doi:10.1001/jama.2017.6028

Nonreproducibility of Preclinical Research

Abstract Full Text
JAMA. 2017;317(23):2452. doi:10.1001/jama.2017.5967

Nonreproducibility of Preclinical Research—Reply

Abstract Full Text
JAMA. 2017;317(23):2453. doi:10.1001/jama.2017.5987
Correction

Typographical and Data Errors

Abstract Full Text
free access
JAMA. 2017;317(23):2453. doi:10.1001/jama.2017.7019
Medical News & Perspectives

Junk Food Ads Reach Children Despite Food Industry Self-regulation

Abstract Full Text
JAMA. 2017;317(23):2359-2361. doi:10.1001/jama.2017.4653

This Medical News article reveals how the food industry markets unhealthful products to kids.

Global Health

Podoconiosis Is the Diagnosis

Abstract Full Text
JAMA. 2017;317(23):2362. doi:10.1001/jama.2017.6505

Cholera Vaccine Safe During Pregnancy

Abstract Full Text
JAMA. 2017;317(23):2362. doi:10.1001/jama.2017.7312

Blood-Clotting Drug Saves Lives During Childbirth

Abstract Full Text
JAMA. 2017;317(23):2362. doi:10.1001/jama.2017.7314
News From the Food and Drug Administration

Antioxidant Drug Approved for ALS

Abstract Full Text
JAMA. 2017;317(23):2363. doi:10.1001/jama.2017.6974

Immunotherapy for Bladder Cancer

Abstract Full Text
JAMA. 2017;317(23):2363. doi:10.1001/jama.2017.6976

Warnings for Anesthetic Drugs

Abstract Full Text
JAMA. 2017;317(23):2363. doi:10.1001/jama.2017.6977
Poetry and Medicine

Under Our Noses

Abstract Full Text
JAMA. 2017;317(23):2454. doi:10.1001/jama.2017.1115
JAMA Revisited

The Patent Laws and Patent Office Practice

Abstract Full Text
JAMA. 2017;317(23):2455. doi:10.1001/jama.2017.5056
JAMA Patient Page

Screening for Obesity in Children and Adolescents

Abstract Full Text
free access
JAMA. 2017;317(23):2460. doi:10.1001/jama.2017.7044
JAMA Masthead

JAMA

Abstract Full Text
free access
JAMA. 2017;317(23):2351-2352. doi:10.1001/jama.2016.13175
×